Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 15/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558208 | 1.00 | ADRB2 (0.46) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL19770228 | 0.96 | ADRB2 (0.43) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL22829253 | 0.96 | ADRB2 (0.43) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL776477 | 0.91 | ADRB2 (0.49) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL776402 | 0.89 | ADRB2 (0.59) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL17979458 | 0.87 | ADRB2 (0.49) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL17979457 | 0.87 | ADRB2 (0.49) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL962871 | 0.87 | ADRB2 (0.45) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL776543 | 0.87 | ADRB2 (0.45) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL13708455 | 0.87 | ADRB2 (0.45) | ADRB2ADRB1ADRB3CHRM2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566785-B2 | Amidine substituted aryl aniline compounds | THERAVANCE, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| EP-1786762-A2 | AMIDINE SUBSTITUTED ARYL ANILINE COMPOUNDS | Theravance, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006031556-A2 | AMIDINE SUBSTITUTED ARYL ANILINE COMPOUNDS | THERAVANCE. INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058530-A1 | Amidine substituted aryl aniline compounds | THERAVANCE, INC. | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058530-A1 | Amidine substituted aryl aniline compounds | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.